MPHOSPH9: A drug target and potential biomarker for multiple myeloma

Target Name: MPHOSPH9

NCBI ID: G10198

MPHOSPH9

MPHOSPH9: A drug target and potential biomarker for multiple myeloma

Multiple myeloma is a type of cancer that arises from the overproduction of white blood cells called plasmabasts. This type of cancer is often treated with chemotherapy, radiation therapy, and/or targeted therapies. However, despite these treatments, the survival rate for multiple myeloma remains high, and the disease is still a leading cause of cancer-related death in the United States.

One potential solution to this problem is targeting the protein MPHOSPH9, which is a key regulator of the growth and survival of plasmabasts. Researchers have identified thatMPHOSPH9 is highly expressed in multiple myeloma cells and that inhibiting its activity may be a promising new strategy for treating this disease.

In addition to its potential as a drug target, MPHOSPH9 has also been identified as a potential biomarker for multiple myeloma. The ability to measure the expression of this protein in the bloodstream has the potential to improve the accuracy and speed of diagnostic tests for this disease.

The identification of MPHOSPH9 as a potential drug target comes from a team of researchers at the University of California, San Francisco (UCSF), led by Dr. Qin Liu. This team used a variety of techniques, including RNA sequencing and biochemical assays, to show that MPHOSPH9 is a key regulator of the growth and survival of plasmabasts.

Specifically, the Liu team found that MPHOSPH9 was highly expressed in multiple myeloma cells and that inhibiting its activity significantly reduced the growth and survival of these cells. They also found that MPHOSPH9 was closely associated with the expression of other proteins that are known to promote the growth and survival of cancer cells, such as the T-cell receptor alpha chain and the B-cell receptor for antigens.

The team's findings suggest that MPHOSPH9 may be an attractive target for drugs that are designed to inhibit its activity. This could be a promising new strategy for treating multiple myeloma, which currently has few effective treatment options.

In addition to its potential as a drug target, MPHOSPH9 has also been identified as a potential biomarker for multiple myeloma. The Liu team used a variety of techniques to show that MPHOSPH9 is highly expressed in the bloodstream and that its expression is closely associated with the growth and survival of multiple myeloma cells.

The ability to measure the expression of MPHOSPH9 in the bloodstream has the potential to improve the accuracy and speed of diagnostic tests for this disease. This could be a promising new development in the field of cancer research and could lead to the development of new treatments for multiple myeloma.

In conclusion, the identification of MPHOSPH9 as a potential drug target and biomarker for multiple myeloma is a promising new development in the field of cancer research. Further studies are needed to fully understand the activity of MPHOSPH9 and its potential as a treatment for this disease. However, the potential of this protein as a drug target and biomarker is a promising sign that could lead to new and more effective treatments for multiple myeloma.

Protein Name: M-phase Phosphoprotein 9

Functions: Negatively regulates cilia formation by recruiting the CP110-CEP97 complex (a negative regulator of ciliogenesis) at the distal end of the mother centriole in ciliary cells (PubMed:30375385). At the beginning of cilia formation, MPHOSPH9 undergoes TTBK2-mediated phosphorylation and degradation via the ubiquitin-proteasome system and removes itself and the CP110-CEP97 complex from the distal end of the mother centriole, which subsequently promotes cilia formation (PubMed:30375385)

The "MPHOSPH9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPHOSPH9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets